Neurogene Inc
NASDAQ:NGNE

Watchlist Manager
Neurogene Inc Logo
Neurogene Inc
NASDAQ:NGNE
Watchlist
Price: 22.77 USD -14.04% Market Closed
Market Cap: 324.9m USD

During the last 3 months Neurogene Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 11% over this period (open performance analysis).

The last transaction was made on May 14, 2025 by Cobb Stuart , who sold 103k USD worth of NGNE shares.

Last Transactions:
Cobb Stuart
$-103k
Cvijic Christine Mikail
$-76.2k
Akkaraju Srinivas
$+516.8k
Cvijic Christine Mikail
$+491.4k
Mcminn Rachel
$+969k
View All Transactions

During the last 3 months Neurogene Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 11% over this period (open performance analysis).

The last transaction was made on May 14, 2025 by Cobb Stuart , who sold 103k USD worth of NGNE shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
179.3k USD
2
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
0
0 USD
9-12
months
3
2m USD

Neurogene Inc
Insider Trading Chart

Neurogene Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Neurogene Inc
Last Insider Transactions

Global
Insiders Monitor

Neurogene Inc
Glance View

Market Cap
324.9m USD
Industry
Biotechnology

Neurogene Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neurogene Inc., formerly Neoleukin Therapeutics, Inc., is focused on developing genetic medicines for patients and their families affected by rare, devastating neurological diseases. The firm is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. The firm's product candidate, NGN-401, is an investigational adeno-associated virus (AAV9) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize therapeutic activity while averting transgene overexpression toxicities. The firm is also developing NGN-101 for the treatment of CLN5 Batten disease. The company is advancing multiple discovery-stage candidates leveraging its EXACT transgene regulation technology.

NGNE Intrinsic Value
9.86 USD
Overvaluation 57%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top